Glufosfamide threshold brain delivery
WebMay 3, 2004 · OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of two treatment arms: Arm I: Patients receive glufosfamide IV over 1 hour on day 1. Arm II: Patients receive glufosfamide as in arm I. Patients are hydrated with excess physiological saline solution 4 hours before and for 3 hours after treatment with … WebSep 15, 2004 · Threshold begins Phase III pancreatic cancer trial for glufosfamide following special protocol assessment agreement from FDA, the firm announces Sept. …
Glufosfamide threshold brain delivery
Did you know?
WebMTD of glufosfamide administered every 28 days in combi-nation with standard dose gemcitabine administered weekly for 3 weeks of every 4 week cycle. Glufosfamide was admin-istered intravenously over 4 h on day 1 of every 4-week cycle. Glufosfamide doses started at 1,500 mg/m2 and esca-lated to 2,500, 3,500 and 4,500 mg/m2 in cohorts of three WebApr 6, 2000 · Arm II: Patients receive glufosfamide as in arm I. Patients are hydrated with excess physiological saline solution 4 hours before and for 3 hours after treatment with glufosfamide. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. ... Conditions: Brain and Central Nervous System Tumors . …
WebGlufosfamide is a novel small molecule that has been evaluated by Threshold in a Phase 3 clinical trial and multiple Phase 2 clinical trials. Under the agreement, Eleison is … WebSep 28, 2006 · Last month the Company announced that it had completed enrollment in a pivotal phase 3 clinical trial evaluating glufosfamide for the potential second-line treatment of pancreatic cancer and a phase 2 clinical trial evaluating glufosfamide in combination with gemcitabine for the potential first-line treatment of pancreatic cancer.
WebOct 26, 2009 · Eleison plans to secure funding to support further development of glufosfamide. Threshold, which is eligible for profit sharing, originally licensed glufosfamide from Baxter International Inc. (NYSE:BAX, Deerfield, Ill.) in 2003 and was developing the compound in Japan with MediBIC Group (Tokyo:2369, Tokyo, Japan). … WebOct 3, 2006 · The Phase III trial will evaluate approximately 300 previously treated patients with locally advanced and/or metastatic pancreatic cancer who receive best supportive …
WebSep 27, 2007 · The median survival of patients who were treated with glufosfamide was 105 days (3.45 months) versus 84 days (2.76 months) for the patients who received …
WebThere was an 18% increase in overall survival for glufosfamide that was not statistically significant: hazard ratio (HR) 0.85 (95% confidence interval (CI) 0.66-1.08, p=0.19). … download sling tv app for windowsWebMar 8, 2016 · Background. Glufosfamide (GLU) is a glucose conjugate of ifosfamide in which isophosphoramide mustard is glycosidically linked to the β-D-glucose molecule. Based on GLU structure, it is considered a targeted chemotherapy with fewer side effects. The main objective of the current study is to assess the cytotoxic potential of GLU for the … download slingplayer app for windows 10WebJul 28, 2007 · Glufosfamide (Threshold Pharmaceuticals, Redwood City, CA) is a new cytotoxic alkylating agent prodrug in which isophosphoramide mustard (IPM) is glycosidically linked to β-D-glucose. ... Patients were excluded from the study if they had previously received gemcitabine, if they had symptomatic brain metastases, radiation therapy … class search bellevue collegeWebJan 31, 2005 · Our data suggests that a disfunction in glutamate-glutamine cycle in the brain may play a role in the pathophysiology of schizophrenia. Elevated … download sling tv app for laptopWebGlufosfamide was compared to best supportive care on 303 randomised patients. There was an 18% increase in OS for glufosfamide that was not statistically significant: HR = 0.85, [0.66–1.08]; P = 0.19) [75]. A randomised phase II study evaluated raltitrexed with … A.L. Inselman, D.K. Hansen, in Encyclopedia of Toxicology (Third … Corinna Weber-Schöndorfer, Christof Schaefer, in Drugs During Pregnancy … In Meyler's Side Effects of Drugs (Sixteenth Edition), 2016. Organs and systems … The glycoconjugate drug (glufosfamide) exhibited 4.5-fold decreased toxicity in … class search ga southernWebGlufosfamide is an alkylating agent consisting of iphosphoramide mustard conjugated to glucose that is currently included in clinical studies of pancreatic cancer. We studied the … classsearchpathWebMay 20, 2008 · 10591 Background: Glufosfamide is glucose linked to isophosphoramide mustard, the active metabolite of ifosfamide. Ifosfamide is known to have activity in soft tissue sarcoma. The objectives of this study are to evaluate the safety and efficacy of GLU in patients (pts) with soft tissue sarcoma. Methods: This 1-stage phase 2 study planned to … class search green river